

Prof. Adnan AYDINER



Personal Information

Email: aaydiner@istanbul.edu.tr

Web: <http://aves.istanbul.edu.tr/905/>

Address: İstanbul Üniversitesi İstanbul Tıp Fakültesi Çapa Fatih İstanbul

International Researcher IDs

ORCID: 0000-0002-1104-5840

Publons / Web Of Science ResearcherID: AAU-4591-2020

Yoksis Researcher ID: 100819



Certificates, Courses and Trainings

Vocational Training, ASCO 2023, ASCO 2023, 2023

Vocational Course, 7.06.1X: CELL BIOLOGY: TRANSPORT AND SIGNALING, MIT, 2023

Vocational Training, SAN ANTONIO 2022, SAN ANTONIO 2022, 2022

Vocational Training, ASCO 2022, ASCO 2022, 2022

Vocational Course, MCB63X: PRINCIPLES OF BIOCHEMISTRY, HARVARD, 2021

Research Areas

Oncology

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases**
Kahraman S., Karakaya S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., HAMDARD J., Yildirim S., Dogan T., Isik S., et al.
Scientific Reports, vol.14, no.1, 2024 (SCI-Expanded)
- II. **Comparative analysis of doublet chemotherapy regimens plus bevacizumab in patients with recurrent ovarian cancer**
Khanmammadov N., Doğan I., Okay N. S., AZİZY A., Saip P., AYDINER A.
Medicine (United States), vol.103, no.1, 2024 (SCI-Expanded)
- III. **Outcomes of the patients with metastatic male breast cancer**
Dogan I., Khanmammadov N., ÖZKURT S., AYDINER A., Saip P.
Journal of Cancer Research and Therapeutics, vol.20, no.1, pp.98-102, 2024 (SCI-Expanded)
- IV. **Evaluation of immune density, PD-L1, and CXCR4 expressions in metaplastic breast carcinoma to predict potential immunotherapy benefit.**
Bagbudar S., KARANLIK H., Cabioglu N., Bayram A., Tükenmez M., AYDINER A., Yavuz E., Onder S.
Medical oncology (Northwood, London, England), vol.41, no.1, pp.18, 2023 (SCI-Expanded)
- V. **Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression**
DOĞAN İ., Aydın E., KHANMAMMADOV N., Paksoy N., Saip P., AYDINER A.

Scientific Reports, vol.13, no.1, 2023 (SCI-Expanded)

- VI. **Long-term outcomes and predictors of recurrence in node-negative early stage breast cancer patients**
DOĞAN İ., Aydin E., KHANMAMMADOV N., Paksoy N., Ferhatoğlu F., AK N., Emiroglu S., İBİŞ K., Onder S., Tukenmez M., et al.
Journal of Cancer Research and Clinical Oncology, vol.149, no.16, pp.14833-14841, 2023 (SCI-Expanded)
- VII. **Efficacy and outcomes of systemic chemotherapy in posttransplant and immunosuppression associated Kaposi sarcoma: Twenty years experience of a tertiary cancer center**
Khanmammadov N. A., Paksoy N., DOĞAN İ., Ferhatoğlu F., Saip P., Aydinler A.
Medicine, vol.102, no.39, 2023 (SCI-Expanded)
- VIII. **The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study)**
Hizal M., Bilgin B., Paksoy N., Atci M. M., KAHRAMAN S., Kilickap S., Guven D. C., KESKİNKILIÇ M., Ayhan M., Eren O., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.149, no.8, pp.4141-4148, 2023 (SCI-Expanded)
- IX. **Outcomes and Prognostic Factors in HER2-Positive Metastatic Breast Cancer Patients Who Had Developed Brain Metastasis in the Treatment Process**
Dogan I., Kizildag İ., Özkurt S., Ibis K., Vatansever S., Saip P., Aydinler A.
ONCOLOGY, vol.101, no.4, pp.262-269, 2023 (SCI-Expanded)
- X. **Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer**
Kahraman S., Erul E., Seyyar M., GÜMÜŞAY Ö., Bayram E., Demirel B. C., Acar O., AKSOY S., Baytemur N. K., ŞAHİN E., et al.
Future oncology (London, England), vol.19, no.10, pp.727-736, 2023 (SCI-Expanded)
- XI. **Demographic and Clinical Features of Patients with Metastatic Breast Cancer: A Retrospective Multicenter Registry Study of the Turkish Oncology Group**
DOĞAN İ., AKSOY S., Cakar B., BAŞARAN G., Ercelep O., Molinas Mandel N., KORKMAZ T., Gokmen E., Sener C., AYDINER A., et al.
Cancers, vol.15, no.6, 2023 (SCI-Expanded)
- XII. **Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy**
Karacin C., Oksuzoglu B., Demirci A., KESKİNKILIÇ M., Baytemür N. K., Yılmaz F., Selvi O., Erdem D., Avşar E., Paksoy N., et al.
BMC cancer, vol.23, no.1, pp.136, 2023 (SCI-Expanded)
- XIII. **Diverging prognostic effects of CD155 and CD73 expressions in locally advanced triple-negative breast cancer**
CABIOĞLU N., BAYRAM A., EMİROĞLU S., ÖNDER S., Karatay H., Oner G., TÜKENMEZ M., Muslumanoglu M., Igci A., AYDINER A., et al.
FRONTIERS IN ONCOLOGY, vol.13, 2023 (SCI-Expanded)
- XIV. **Atezolizumab combined with chemotherapy in the first-line treatment of extensive-stage small cell lung cancer: a real-life data of the Turkish Oncology Group**
Gurbuz M., Kutlu Y., AKKUŞ E., KÖKSOY E. B., Kose N., Oven B. B., Uluc B. O., Demiray A. G., Erdem D., Demir B., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.148, no.12, pp.3547-3555, 2022 (SCI-Expanded)
- XV. **Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study**
PAKSOY N., KHANMAMMADOV N., DOĞAN İ., FERHATOĞLU F., YILDIZ A., AK N., AYDINER A.
Medicine (United States), vol.101, no.45, 2022 (SCI-Expanded)
- XVI. **Abbreviated and Standard Breast MRI in Neoadjuvant Chemotherapy Response Evaluation: A Comparative Study.**
Yirgin İ., Engin G., Yildiz Ş., Aydin E. C., Karanlik H., Cabioglu N., Tukenmez M., Emiroglu S., Semen Onder S. O., Yildiz S., et al.

Current medical imaging, vol.18, pp.1052-1060, 2022 (SCI-Expanded)

- XVII. Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC**
DOĞAN İ., Gurbuz M., Paksoy N., Ferhatoglu F., Vatansever S., Saip P., DEMİRKAZIK A., Aydiner A.
MEDICINE, vol.101, no.34, 2022 (SCI-Expanded)
- XVIII. Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study**
Hizal M., Bilgin B., Paksoy N., Kilickap S., Atci M. M., KAHRAMAN S., KESKİNKILIÇ M., Bilgetekin I., Ayhan M., Tural D., et al.
FUTURE ONCOLOGY, vol.18, pp.2573-2582, 2022 (SCI-Expanded)
- XIX. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study**
Hizal M., Bilgin B., Paksoy N., Acikgoz O., Sezer A., Gurbuz M., Ak N., Yucel S., Ayhan M., EROL C., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.148, no.6, pp.1501-1508, 2022 (SCI-Expanded)
- XX. Recurrent autoimmune encephalitis related to immune checkpoint inhibitors**
Ser M. H., Samanci N. S., Naziye A. K., Aydiner A., Ozkara C.
EPILEPTIC DISORDERS, vol.24, no.3, pp.609-613, 2022 (SCI-Expanded)
- XXI. Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.**
Dogan I., Paksoy N., Ak N., Vatansever S., Saip P., Aydiner A.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.16, 2022 (SCI-Expanded)
- XXII. Outcomes and prognostic factors in patients with HER2-positive metastatic breast cancer with brain metastasis.**
Dogan I., Yirgin I. K., Ozkurt S., Ibis K., Vatansever S., Saip P., Aydiner A.
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.16_suppl, pp.14002, 2022 (SCI-Expanded)
- XXIII. Are false-negative rates of sentinel lymph node biopsy after neoadjuvant chemotherapy really associated with poor prognosis in clinically node-positive disease at diagnosis?**
Cabioglu N., Karanlik H., Igci A., Muslumanoglu M., Tukenmez M., Emiroglu S., Ozkurt E., Yildirim N., Ilgun S., Onder S., et al.
ANNALS OF SURGICAL ONCOLOGY, vol.29, no.SUPPL 1, pp.310-311, 2022 (SCI-Expanded)
- XXIV. Efficacy and safety of trastuzumab emtansine in older patients with HER2-positive advanced breast cancer: a real-world study**
Cil I., Kucukarda A., Atci M. M., Secmeler S., Paksoy N., Ferhatoglu F., Ak N., Ayhan M., Ozyukseler D. T., Onder A. H., et al.
TUMORI JOURNAL, vol.108, no.1, pp.19-25, 2022 (SCI-Expanded)
- XXV. Demonstration of in vivo estrogen receptor status with 16 alpha- [F-18]fluoro-17 beta-oestradiol (FES) PET/CT in a rare case of benign metastasizing leiomyoma**
Has Simsek D., Kuyumcu S., Ozkan Z. G., Vuralli Bakkaloglu D., Bayram A., Topuz S., Aydiner A., Sanli Y.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, vol.48, no.12, pp.4101-4102, 2021 (SCI-Expanded)
- XXVI. Clinicopathological and Prognostic Features of 67 Cases with Pulmonary Sarcomatoid Carcinoma: An 18-Year Single-Centre Experience**
Ferhatoglu F., Amirov F., Ozkan B., Kara M., Toker A., Ak N., Aydın E., Paksoy N., Yilmazbayhan D., Aydiner A.
ONCOLOGY RESEARCH AND TREATMENT, no.11, pp.590-600, 2021 (SCI-Expanded)
- XXVII. Nivolumab treatment for metastatic thymic epithelial tumors.**
Ak N., Aydiner A.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners, vol.27, pp.1710-1715, 2021 (SCI-Expanded)
- XXVIII. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study.**

Cabioğlu N., Karanlık H., Yıldırım N., Müslümanoğlu M., Çakmak Karadeniz G., Trabulus Can D., Tükenmez M., Ersoy Y. E., Uras C., Zengel B., et al.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, vol.47, no.10, pp.2506-2514, 2021 (SCI-Expanded)

XXIX. Sentinel Lymph Node Biopsy May Prevent Unnecessary Axillary Dissection in Patients with Inflammatory Breast Cancer Who Respond to Systemic Treatment

Karanlık H., CABIOĞLU N., Oprea A. L., ÖZGÜR İ., AK N., AYDINER A., ÖNDER S., BADEMLER S., GÜLLÜOĞLU M. B. BREAST CARE, vol.16, no.5, pp.468-474, 2021 (SCI-Expanded)

XXX. Outcomes of thymoma after multimodal therapy and determinants of survival: A 16-year experience of a tertiary cancer center

Ak N., Toker A., Kara M., Ozkan B., Ulker M., Kaba E., Yegen G., Karaman S., Dagoglu N., Saglam E. K., et al. TURK GOGUS KALP DAMAR CERRAHISI DERGISI-TURKISH JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, vol.29, no.4, pp.487-495, 2021 (SCI-Expanded)

XXXI. Clinical impact of PD-L1 expression in triple-negative breast cancer patients with residual tumor burden after neoadjuvant chemotherapy

Oner G., Onder S., Karatay H., Ak N., Tukenmez M., Muslumanoglu M., Igci A., Dincag A., Ozmen V., Aydinler A., et al. WORLD JOURNAL OF SURGICAL ONCOLOGY, vol.19, no.1, 2021 (SCI-Expanded)

XXXII. The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study

Ak N., Ozkan B., Yenigun M. B., Yilmazbayhan D., Toker A., Ferhatoglu F., Yasar A., SAK S., Tanju S., Dilege S., et al. JOURNAL OF BUON, vol.26, no.3, pp.819-829, 2021 (SCI-Expanded)

XXXIII. Long-term outcomes and predictors of recurrence in patients with early-stage node negative breast cancer.

Dogan I., Aydin E., Paksoy N., Ferhatoglu F., Ak N., Ibis K., Onder S., Tukenmez M., Cabioğlu N., Muslumanoglu M., et al. JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (SCI-Expanded)

XXXIV. Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors.

Aydiner A., Dogan I., Khanmammadov N., Saip P., Vatansever S. JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.15, 2021 (SCI-Expanded)

XXXV. TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer

Cabioğlu N., Onder S., Oner G., Karatay H., Tukenmez M., Muslumanoglu M., Igci A., Eralp Y., Aydinler A., Saip P., et al. BMC CANCER, vol.21, no.1, 2021 (SCI-Expanded)

XXXVI. Outcomes of metastatic male breast cancer

Dogan I., Khanmammadov N., Aydinler A., Saip P. CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)

XXXVII. Tim3 expression on tumor infiltrating lymphocytes is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple negative breast cancer

Cabioğlu N., Onder S., Oner G., Karatay H., Tukenmez M., Muslumanoglu M., Igci A., Eralp Y., Aydinler A., Saip P., et al. CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)

XXXVIII. Sentinel lymph node biopsy alone in locally advanced breast cancer after neoadjuvant chemotherapy: Turkish multicentric neosenti-turk MF-18-02-study

Cabioğlu N., Karanlık H., Muslumanoglu M., Cakmak G. K., Trablus D. C., Tukenmez M., Ersoy Y. E., URAS C., Zengel B., Emiroglu S., et al. CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)

XXXIX. Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer

Dogan I., Aydin E., Khanmammadov N., Aydinler A., Saip P. CANCER RESEARCH, vol.81, no.4, 2021 (SCI-Expanded)

XL. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123

NSCLC patients

Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., Demirci U., Christopoulos P., ÇİÇİN İ., Basal F. B., et al.

LUNG CANCER, vol.148, pp.48-54, 2020 (SCI-Expanded)

- XLII. **Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial**
Demir A., Mandel N. M., PAYDAŞ S., Demir G., ER O., Turhal N. S., Bavbek S., Eralp Y., Saip P. M., Guler E. N., et al.
BALKAN MEDICAL JOURNAL, vol.37, no.2, pp.104-107, 2020 (SCI-Expanded)
- XLIII. **Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naïve non-small cell lung carcinoma and the response to erlotinib therapy**
Sari M., Aydinler A.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, vol.16, no.1, pp.132-138, 2020 (SCI-Expanded)
- XLIII. **High expression of pdl-1 in patients with triple negative breast cancer with residual tumor burden after neoadjuvant chemotherapy.**
Oner G., Önder S., Karatay H., Tükenmez M., Muslumanoglu M., Igci A., Dinccag A., Özmen V., Aydinler A., Yavuz E., et al.
JOURNAL OF CLINICAL ONCOLOGY, vol.36, 2018 (SCI-Expanded)
- XLIV. **Epidermal growth factor receptor (EGFR) exon 20 mutations in EGFR-tyrosine kinase inhibitors (EGFR-TKIs) naïve non-small cell lung carcinoma (NSCLC) and response to erlotinib therapy**
AYDINER A., Sari M.
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- XLV. **Effect of the childhood trauma on the adjustment to cancer in the patients with breast cancer**
Guveli H., Guveli M. E., Sen F., Oflaz S., Gurdal N., Tambas M., Kucucuk S., Aydinler A., Ozkan M.
BREAST CANCER, vol.24, no.4, pp.544-551, 2017 (SCI-Expanded)
- XLVI. **Concomitant etoposide and cisplatin provided improved survival compared with docetaxel and cisplatin in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy**
Sen F., Tambas M., Ozkaya K., Guveli M. E., Ciftci R., Ozkan B., Oral E. N., Saglam E. K., Saip P., Toker A., et al.
MEDICINE, vol.95, no.30, 2016 (SCI-Expanded)
- XLVII. **Factors affecting progression-free survival in non-HIV-related Kaposi sarcoma**
Sen F., Tambas M., Ciftci R., Toz B., Kilic L., Bozbey H. U., Karanlik H., Kurul S., Vatansever S., Oral E. N., et al.
JOURNAL OF DERMATOLOGICAL TREATMENT, vol.27, no.3, pp.275-277, 2016 (SCI-Expanded)
- XLVIII. **Combination of adjuvant chemotherapy and radiotherapy is associated with improved survival at early stage type II endometrial cancer and carcinosarcoma**
Sozen H., Ciftci R., Vatansever D., Topuz S., Iyibozkurt A. C., Bozbey H. U., Yasa C., Cali H., Yavuz E., Kucucuk S., et al.
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY, vol.56, no.2, pp.199-206, 2016 (SCI-Expanded)
- XLIX. **Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer Survival and Response to Treatment**
Aydiner A., Sen F., Tambas M., Ciftci R., Eralp Y., Saip P., Karanlik H., Fayda M., Kucucuk S., Onder S., et al.
MEDICINE, vol.94, no.52, 2015 (SCI-Expanded)
- L. **Is there any effect of first-day usage of a totally implantable venous access device on complications?**
Karanlik H., Odabas H., Yildirim I., Ozgur I., Kilic B., Sen F., Kurul S., Aydinler A.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.20, no.6, pp.1057-1062, 2015 (SCI-Expanded)
- LI. **Concomitant Chemoradiotherapy with Etoposide & Cisplatin versus Docetaxel & Cisplatin in Locally Advanced Non-Small Cell Lung Cancer**
Eralp Y., Sen F., Tambas M., Ozkaya K., Ozkan B., Oral E. N., Saglam E. K., Firat P., Saip P., Toker A., et al.
JOURNAL OF THORACIC ONCOLOGY, vol.10, no.9, 2015 (SCI-Expanded)
- LII. **Renin-Angiotensin System Blockers May Prolong Survival of Metastatic Non-Small Cell Lung Cancer Patients Receiving Erlotinib**
Aydiner A., Ciftci R., Sen F.

MEDICINE, vol.94, no.22, 2015 (SCI-Expanded)

- LIII. **Effects of Distant Reiki On Pain, Anxiety and Fatigue in Oncology Patients in Turkey: A Pilot Study.**
DEMIR M., Can G., KELAM A., AYDINER A.
Asian Pacific journal of cancer prevention : APJCP, vol.16, pp.4859-62, 2015 (SCI-Expanded)
- LIV. **A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer**
Yildiz I., Tas F., Kilic L., Sen F., Saip P., Eralp Y., Keskin S., Karabulut S., Ciftci R., Serilmez M., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.72, no.2, pp.437-444, 2013 (SCI-Expanded)
- LV. **A comparison of men and women's experiences of chemotherapy-induced alopecia**
Can G., Demir M., Erol O., Aydinler A.
EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.17, no.3, pp.255-260, 2013 (SCI-Expanded)
- LVI. **Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women**
Aydiner A.
BREAST, vol.22, no.2, pp.121-129, 2013 (SCI-Expanded)
- LVII. **Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients**
Aydiner A., Kilic L., Yildiz I., Keskin S., Sen F., Kucucuk S., Karanlik H., Muslumanoglu M., Igci A.
MEDICAL ONCOLOGY, vol.30, no.1, 2013 (SCI-Expanded)
- LVIII. **The efficiency of the acupuncture in prevention of the chemotherapy-induced nausea and vomiting**
Genc A., Can G., Aydinler A.
SUPPORTIVE CARE IN CANCER, vol.21, no.1, pp.253-261, 2013 (SCI-Expanded)
- LIX. **Does Beta-blocker Therapy Improve the Survival of Patients with Metastatic Non-small Cell Lung Cancer?**
Aydiner A., Ciftci R., Karabulut S., Kilic L.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.10, pp.6109-6114, 2013 (SCI-Expanded)
- LX. **Clinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status**
Aydiner A., Yildiz I., Seyidova A.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.5, pp.3255-3261, 2013 (SCI-Expanded)
- LXI. **Effects of alopecia on body image and quality of life of Turkish cancer women with or without headscarf**
Erol O., Can G., Aydinler A.
SUPPORTIVE CARE IN CANCER, vol.20, no.10, pp.2349-2356, 2012 (SCI-Expanded)
- LXII. **Association of clinical and pathological variables with survival in thymoma.**
Aydiner A., Toker A., Sen F., Bicakci E., Saglam E. K., Erus S., Eralp Y., Tas F., Oral E. N., Topuz E., et al.
Medical oncology (Northwood, London, England), vol.29, no.3, pp.2221-8, 2012 (SCI-Expanded)
- LXIII. **Taxane-induced nail changes: Predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity**
Can G., Aydinler A., Cavdar I.
EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.16, no.3, pp.270-275, 2012 (SCI-Expanded)
- LXIV. **The roles of surgery and EMA/CO chemotherapy regimen in primary refractory and non-refractory gestational trophoblastic neoplasia**
Aydiner A., Keskin S., Berkman S., Bengisu E., Ilhan H. R., Tas F., Topuz E.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.138, no.6, pp.971-977, 2012 (SCI-Expanded)
- LXV. **Complementary and Alternative Therapies Used by Turkish Breast Cancer Patients Undergoing Chemotherapy**
Can G., Demir M., Aydinler A.
BREAST CARE, vol.7, no.6, pp.471-475, 2012 (SCI-Expanded)
- LXVI. **Complete Response in a Patient with Granulosa Cell Tumor Treated with a Combination of Leuprolide and Tamoxifen**

Keskin S, Bengisu E, Tuzlali S, Aydiner A.

ONKOLOGIE, vol.35, pp.451-453, 2012 (SCI-Expanded)

- LXVII. Weekly docetaxel and cisplatin with concomitant radiotherapy in addition to surgery and/or consolidation chemotherapy in stage III non-small cell lung cancer**

Sen F, Saglam E. K., Toker A, Dilege S, Kizir A, Oral E. N., Saip P, Sakallioğlu B, Topuz E, Aydiner A.

CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.68, no.6, pp.1497-1505, 2011 (SCI-Expanded)

- LXVIII. A psychometric validation study of the Quality of Life and FAMCARE scales in Turkish cancer family caregivers**

Can G., Akin S., Aydiner A., Ozdilli K., Oskay U., Durna Z.

QUALITY OF LIFE RESEARCH, vol.20, no.8, pp.1319-1329, 2011 (SCI-Expanded)

- LXIX. Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non-Small-Cell Lung Cancer: A Phase II Study**

Aydiner A., Sen F., SAGLAM E. K., Oral E. N., Eralp Y., Tas F., Toker A., Dilege S.

CLINICAL LUNG CANCER, vol.12, no.5, pp.286-292, 2011 (SCI-Expanded)

- LXX. Non-pharmacological interventions used by cancer patients during chemotherapy in Turkey**

Can G., Erol O., Aydiner A., Topuz E.

EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.15, no.2, pp.178-184, 2011 (SCI-Expanded)

- LXXI. Development and validation of the Nightingale Symptom Assessment Scale (N-SAS) and predictors of the quality of life of the cancer patients in Turkey**

Can G., Aydiner A.

EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.15, no.1, pp.3-11, 2011 (SCI-Expanded)

- LXXII. Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy**

Keskin S., Muslumanoglu M., Saip P., Karanlik H., Guveli M., Pehlivan E., Aydoğan F., Eralp Y., Aydiner A., Yavuz E., et al.

ONCOLOGY, vol.81, no.1, pp.30-38, 2011 (SCI-Expanded)

- LXXIII. Quality of life, symptom experience and distress of lung cancer patients undergoing chemotherapy**

Akin S., Can G., Aydiner A., Ozdilli K., Durna Z.

EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.14, no.5, pp.400-409, 2010 (SCI-Expanded)

- LXXIV. The validity and reliability of the Turkish version of the Quality of Life Index [QLI] (Cancer version)**

Can G., Durna Z., Aydiner A.

EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.14, no.4, pp.316-321, 2010 (SCI-Expanded)

- LXXV. The role of third generation agents as an induction treatment in concurrent chemoradiotherapy (CRT) for locally-advanced non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials**

Aydiner A., Can G.

JOURNAL OF THORACIC ONCOLOGY, vol.4, no.9, 2009 (SCI-Expanded)

- LXXVI. Quality of life and complementary and alternative medicine use among cancer patients in Turkey**

Can G., Erol O., Aydiner A., Topuz E.

EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.13, no.4, pp.287-294, 2009 (SCI-Expanded)

- LXXVII. Detection of Human Papillomavirus DNA by PCR and Southern Blot Hybridization in Colorectal cancer Patients**

SALEPCI T., YAZICI ÖZBEK H., DANE F., Topuz E., DALAY M. N., ONAT H., AYKAN N. F., SEKER M., AYDINER A.

JOURNAL OF BUON, vol.14, no.3, pp.495-499, 2009 (SCI-Expanded)

- LXXVIII. Immune changes in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy**

Cabioğlu N., Müslümanoğlu M. E., Tütüncü Y., Adin-Cinar S., Gürel N., KIRAN B., Igci A., Özmen V., DAGOGLU T., Aydiner A., et al.

Turkish Journal of Immunology, vol.13, no.1, pp.15-20, 2008 (SCI-Expanded)

- LXXIX. The quality of life and self-efficacy of Turkish breast cancer patients undergoing chemotherapy**

Akin S., Can G., Durna Z., Aydiner A.

EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.12, no.5, pp.449-456, 2008 (SCI-Expanded)

- LXXX. **Predictive factors for local recurrence after breast conservative surgery following neoadjuvant chemotherapy: Our long-term results Neoadjuvan kemoterapi sonrası meme koruyucu cerrahide lokal nüksü etkileyen faktörler: Uzun dönem sonuçlarımız**
Cabioglu N., Müslümanoğlu M., Iğci A., Özçınar B., Özmen V., Dağoğlu T., Eralp Y., Dinçer M., Aslay I., Yavuz E., et al.
Turk Onkoloji Dergisi, vol.23, no.2, pp.81-90, 2008 (SCI-Expanded)
- LXXXI. **Evaluation of the effect of care given by nursing students on oncology patients' satisfaction**
Can G., Akin S., Aydiner A., Ozdilli K., Durna Z.
EUROPEAN JOURNAL OF ONCOLOGY NURSING, vol.12, no.4, pp.387-392, 2008 (SCI-Expanded)
- LXXXII. **Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer**
Tas F., Derin D., Guney N., Aydiner A., Topuz E.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.4, pp.330-334, 2008 (SCI-Expanded)
- LXXXIII. **Biweekly administration of gemcitabine and cisplatin chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer**
Tas F., Guney N., Derin D., Camlica H., Aydiner A., Topuz E.
INVESTIGATIONAL NEW DRUGS, vol.26, no.4, pp.363-368, 2008 (SCI-Expanded)
- LXXXIV. **Meta-analysis of trials comparing anastrozole and tamoxifen for adjuvant treatment of postmenopausal women with early breast cancer**
Aydiner A., Tas F.
TRIALS, vol.9, 2008 (SCI-Expanded)
- LXXXV. **Evaluation of sexual function of Turkish women with breast cancer receiving systemic treatment**
Can G., Oskay U., DURNA Z., Aydiner A., Saip P., Disci R., Kadioglu A.
ONCOLOGY NURSING FORUM, vol.35, no.3, pp.471-476, 2008 (SCI-Expanded)
- LXXXVI. **A pilot study evaluating the efficacy and toxicity of biweekly gemcitabine and pegylated liposomal doxorubicin in recurrent platinum-resistant epithelial ovarian cancer**
Tas F., Guney N., Derin D., Aydiner A., Topuz E.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.13, no.2, pp.156-160, 2008 (SCI-Expanded)
- LXXXVII. **Memenin filloides tümörlerinde tedavi yaklaşımları**
CABIOĞLU N., ÇELİK O. T., ÖZMEN V., İĞCİ A., MÜSLÜMANOĞLU M. E., ÖZÇINAR B., ÖZLÜK M. Y., DURSUN M., DAĞOĞLU T., ASLAY I., et al.
Meme Sağlığı Dergisi, vol.4, pp.99-104, 2008 (SCI-Expanded)
- LXXXVIII. **Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer**
Derin D., Eralp Y., Ozluk Y., Yavuz E., Guney N., Saip P., Igci A., Ozmen V., Kucucuk S., Aslay I., et al.
CANCER INVESTIGATION, vol.26, no.7, pp.671-679, 2008 (SCI-Expanded)
- LXXXIX. **Gemcitabine and cisplatin as neo-adjuvant chemotherapy for non-small cell lung cancer: A phase II study**
Aydiner A., Kiyik M., Cikrikcioglu S., Kosar F., Gurses A., Turna A., Yazar A., Dilege S., Goksel T., Cakan A.
LUNG CANCER, vol.58, no.2, pp.246-252, 2007 (SCI-Expanded)
- XC. **Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma**
Tas F., Derin D., Guney N., Camlica H., Aydiner A., Topuz E.
LUNG CANCER, vol.57, no.1, pp.79-83, 2007 (SCI-Expanded)
- XCI. **The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer**
Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., Tas F., Aydiner A., Topuz E.
MEDICAL ONCOLOGY, vol.24, no.1, pp.39-43, 2007 (SCI-Expanded)
- XCII. **Increased sister chromatid exchange frequency in young women with breast cancer and in their first-degree relatives.**
Cefle K., Ucur A., Guney N., Ozturk S., Palanduz S., Tas F., Asoglu O., Bayrak A. G., Muslumanoglu M. E., Aydiner A.

Cancer genetics and cytogenetics, vol.171, pp.65-7, 2006 (SCI-Expanded)

- XCIII. Evaluation of prognostic factors and comparison of systemic treatment modalities in patients with recurrent or metastatic endometrial carcinoma**
Karagol H., Saip P., Uygun K., Kucucuk S., Aydiner A., Topuz E.
MEDICAL ONCOLOGY, vol.23, no.4, pp.543-548, 2006 (SCI-Expanded)
- XCIV. Induction and concurrent chemotherapy with concomitant boost radiotherapy in non-small cell lung cancer**
Oral E. N., AYDINER A., ERALP Y., TOPUZ E.
MEDICAL ONCOLOGY, vol.22, no.4, pp.367-374, 2005 (SCI-Expanded)
- XCV. Thymidine labeling index: Prognostic role in breast cancer**
Bilir A., Eralp Y., Cabioglu N., Agizhali B., Camlica H., Aydiner A.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.27, no.4, pp.400-406, 2004 (SCI-Expanded)
- XCVI. Clinical value of protein S100 and melanoma-inhibitory activity (MIA) in malignant melanoma.**
TAS F., Yasasever V., DURANYILDIZ D., CAMLICA H., USTUNER Z., AYDINER A., TOPUZ E.
American journal of clinical oncology, vol.27, no.3, pp.225-8, 2004 (SCI-Expanded)
- XCVII. T-cell lymphoblastic lymphoma presenting with a breast mass**
Yumuk P., Aydiner A., Topuz E., Cabioglu N., Dogan O.
LEUKEMIA & LYMPHOMA, vol.45, no.4, pp.833-836, 2004 (SCI-Expanded)
- XCVIII. Assessment of fatigue in and care needs of Turkish women with breast cancer**
Can G., Durna Z., Aydiner A.
CANCER NURSING, vol.27, no.2, pp.153-161, 2004 (SCI-Expanded)
- XCIX. Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer - Consolidative intraperitoneal cisplatin in ovarian cancer**
Topuz E., Eralp Y., Saglam S., Saip P., Aydiner A., Berkman S., Yavuz E.
GYNECOLOGIC ONCOLOGY, vol.92, no.1, pp.147-151, 2004 (SCI-Expanded)
- C. Granulosa cell tumor of the ovary: retrospective analysis of 45 cases.**
Uygun K., Aydiner A., Saip P., Basaran M., Tas F., Kocak Z., Dincer M., Topuz E.
American journal of clinical oncology, vol.26, no.5, pp.517-21, 2003 (SCI-Expanded)
- CI. Oral etoposide (VP16) in platinum-resistant epithelial ovarian cancer (EOC)**
Alici S., Saip P., Eralp Y., Aydiner A., Topuz E.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.26, no.4, pp.358-362, 2003 (SCI-Expanded)
- CII. Prognostic factors and survival in patients with metastatic or recurrent carcinoma of the uterine cervix**
Eralp Y., Saip P., Sakar B., Kucucuk S., Aydiner A., Dincer M., Aslay I., Topuz E.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol.13, no.4, pp.497-504, 2003 (SCI-Expanded)
- CIII. Combination chemotherapy with docetaxel and irinotecan in metastatic malignant melanoma.**
Tas F., Camlica H., Kurul S., Aydiner A., Topuz E.
Clinical oncology (Royal College of Radiologists (Great Britain)), vol.15, no.3, pp.132-5, 2003 (SCI-Expanded)
- CIV. Clinical parameters and treatment results in recurrent granulosa cell tumor of the ovary**
Uygun K., Aydiner A., Saip P., Kocak Z., Basaran M., Dincer M., Topuz E.
GYNECOLOGIC ONCOLOGY, vol.88, no.3, pp.400-403, 2003 (SCI-Expanded)
- CV. Inflammatory breast cancer: Results of anthracycline-based neoadjuvant chemotherapy**
Ozmen V., Cabioglu N., Igci A., Dagoglu T., AYDINER A., Kecer M., Bozfakioglu Y., Dinçer M., Bilir A., Topuz E.
Breast Journal, vol.9, no.2, pp.79-85, 2003 (SCI-Expanded)
- CVI. Efficacy of cisplatin and cyclophosphamide combination for recurrent and metastatic carcinoma of the uterine cervix.**
Eralp Y., Saip P., Sakar B., Tas F., Aydiner A., Topuz E.
European journal of gynaecological oncology, vol.24, pp.323-6, 2003 (SCI-Expanded)

- CVII. **Resectable thymoma: Treatment outcome and prognostic factors in the late adolescent and adult age group**
 ERALP Y., AYDINER A., KIZIR A., KAYTAN E., ORAL E., TOPUZ E.
 CANCER INVESTIGATION, vol.21, no.5, pp.737-743, 2003 (SCI-Expanded)
- CVIII. **Adjuvant intraperitoneal chemotherapy with cisplatin, mitoxantrone, 5-fluorouracil, and calcium folinate in patients with gastric cancer: a phase II study.**
 Topuz E., Basaran M., Saip P., Aydinler A., Argon A., Sakar B., Tas F., Uygun K., Bugra D., Aykan N.
 American journal of clinical oncology, vol.25, no.6, pp.619-24, 2002 (SCI-Expanded)
- CIX. **Anemia in oncology practice: relation to diseases and their therapies.**
 Tas F., Eralp Y., Basaran M., Sakar B., Alici S., Argon A., Bulutlar G., Camlica H., Aydinler A., Topuz E.
 American journal of clinical oncology, vol.25, no.4, pp.371-9, 2002 (SCI-Expanded)
- CX. **Clinical characteristics of gestational trophoblastic disease at a single institute**
 Alici S., Eralp Y., Saip P., Argon A., Basaran M., Topuz E., Aydinler A.
 TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol.197, no.2, pp.95-100, 2002 (SCI-Expanded)
- CXI. **Safety of paclitaxel in a patient with ovarian cancer and hyperbilirubinemia due to Rotor's syndrome.**
 Argon A., Aydinler A., Tas F., Saip P., Topuz E.
 Gynecologic oncology, vol.85, no.2, pp.362-4, 2002 (SCI-Expanded)
- CXII. **Prognostic role of nm23 gene expression in patients with ovarian cancer.**
 Tas F., Tuzlali S., Aydinler A., Saip P., Salihoglu Y., Iplikci A., Topuz E.
 American journal of clinical oncology, vol.25, no.2, pp.164-7, 2002 (SCI-Expanded)
- CXIII. **Acetaminophen modulations of chemotherapy efficacy in MDAH 2774 human endometrioid ovarian cancer cells in vitro**
 BILIR A., ALTINOZ M., Attar E., ERKAN M., AYDINER A.
 NEOPLASMA, vol.49, no.1, pp.38-42, 2002 (SCI-Expanded)
- CXIV. **Prognostic factors in pancreatic carcinoma: serum LDH levels predict survival in metastatic disease.**
 Tas F., Aykan F., Alici S., Kaytan E., Aydinler A., Topuz E.
 American journal of clinical oncology, vol.24, no.6, pp.547-50, 2001 (SCI-Expanded)
- CXV. **Thymidine labeling index in epithelial ovarian cancer**
 Salihoglu Y., Bilir A., Aydinler A., ERKAN M., TUZLALI S., ERALP Y.
 INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, vol.75, no.2, pp.171-176, 2001 (SCI-Expanded)
- CXVI. **Circulating HER-2/NEU levels in patients with melanoma.**
 Eralp Y., Aydinler A., Toptani S., Tas F., Camlica H., Topuz E.
 CLINICAL CANCER RESEARCH, vol.7, no.11, 2001 (SCI-Expanded)
- CXVII. **Stevens-Johnson syndrome in a patient receiving anticonvulsant therapy during cranial irradiation.**
 Eralp Y., Aydinler A., Tas F., Saip P., Topuz E.
 American journal of clinical oncology, vol.24, no.4, pp.347-50, 2001 (SCI-Expanded)
- CXVIII. **Serum lactate dehydrogenase levels at presentation predict outcome of patients with limited-stage small-cell lung cancer.**
 Tas F., Aydinler A., Demir C., Topuz E.
 American journal of clinical oncology, vol.24, no.4, pp.376-8, 2001 (SCI-Expanded)
- CXIX. **Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome**
 Ozmen V., CABIOGLU N., DOLAY K., BILIR A., KECER M., AYDINER A., MUSLUMANOGLU M. E., IGCI A., BOZFAKIOGLU Y., DAGOGLU T.
 BREAST CANCER RESEARCH AND TREATMENT, vol.68, no.2, pp.147-157, 2001 (SCI-Expanded)
- CXX. **Measurement of serum CA 19-9 may be more valuable than CEA in prediction of recurrence in patients with gastric cancer.**
 TAS F., AYKAN F., AYDINER A., Yasasever V., TOPUZ E.
 American journal of clinical oncology, vol.24, no.2, pp.148-9, 2001 (SCI-Expanded)

- CXXI. **5-fluorouracil-induced balanitis in a patient with oesophageal carcinoma.**
Tas F., Basaran M., Aydiner A., Eralp Y., Topuz E.
Clinical oncology (Royal College of Radiologists (Great Britain)), vol.13, no.3, pp.170-1, 2001 (SCI-Expanded)
- CXXII. **The efficacy of combination chemotherapy including intraperitoneal cisplatin and mitoxantrone with intravenous ifosfamide in patients with FIGO stage I C ovarian carcinoma.**
Topuz E., Eralp Y., Saip P., Aydiner A., Taş F., Salihoğlu Y., Berkman S., Bengisu E.
European journal of gynaecological oncology, vol.22, pp.70-3, 2001 (SCI-Expanded)
- CXXIII. **The efficacy of combination chemotherapy including intraperitoneal cisplatin and mitoxantrone with intravenous ifosfamide in patients with FIGO stage IC ovarian carcinoma**
Topuz E., Eralp Y., Saip P., Aydiner A., Tas F., Salihoğlu Y., Berkman S., Bengisu E.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.22, no.1, pp.70-73, 2001 (SCI-Expanded)
- CXXIV. **The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract.**
Topuz E., Eralp Y., Aydiner A., Saip P., Taş F., Yavuz E., Salihoğlu Y.
European journal of gynaecological oncology, vol.22, pp.469-72, 2001 (SCI-Expanded)
- CXXV. **Hypertrophic osteoarthropathy associated with docetaxel treatment.**
Tas F., Aydiner A., Tenekeci N., Karadeniz A. N., Sakar B., Topuz E.
Clinical oncology (Royal College of Radiologists (Great Britain)), vol.13, no.2, pp.145-6, 2001 (SCI-Expanded)
- CXXVI. **Autophagy and nuclear changes in FM3A breast tumor cells after epirubicin, medroxyprogesterone and tamoxifen treatment in vitro**
BILIR A., ALTINOZ M., ERKAN M., Ozmen V., AYDINER A.
PATHOBIOLOGY, vol.69, no.3, pp.120-126, 2001 (SCI-Expanded)
- CXXVII. **Angiogenesis and p53 protein expression in breast cancer - Prognostic roles and interrelationships**
TAS F., Yavuz E., AYDINER A., SAİP P., DISCI R., IPLIKCI A., TOPUZ E.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.23, no.6, pp.546-553, 2000 (SCI-Expanded)
- CXXVIII. **Utility of the serum tumor markers: CYFRA 21.1, carcinoembryonic antigen (CEA), and squamous cell carcinoma antigen (SCC) in squamous cell lung cancer.**
Tas F., Aydiner A., Topuz E., YASASEVER V., Karadeniz A. N., Saip P. M.
Journal of experimental & clinical cancer research : CR, vol.19, no.4, pp.477-81, 2000 (SCI-Expanded)
- CXXIX. **Multiple primary neoplasms at a single institution: differences between synchronous and metachronous neoplasms.**
Aydiner A., Karadeniz A. N., Uygun K., Tas S., Tas F., Disci R., Topuz E.
American journal of clinical oncology, vol.23, no.4, pp.364-70, 2000 (SCI-Expanded)
- CXXX. **Celsite port and catheter as an intraperitoneal access device in the treatment of ovarian cancer.**
Topuz E., Salihoğlu Y., Aydiner A., Saip P., Tas F., Sozen T., Berkman S., Bengisu E.
Journal of surgical oncology, vol.74, pp.223-6, 2000 (SCI-Expanded)
- CXXXI. **Celsite (R) port and catheter as an intraperitoneal access device in the treatment of ovarian cancer**
TOPUZ E., Salihoğlu Y., AYDINER A., Saip P. M., TAS F., SOZEN T., BERKMAN S., BENGISU E.
JOURNAL OF SURGICAL ONCOLOGY, vol.74, no.3, pp.223-226, 2000 (SCI-Expanded)
- CXXXII. **The roles of chemotherapy and surgery in gastric carcinoma and the influence of prognostic factors on survival.**
Tas F., Aykan N., Aydiner A., Uygun K., Basaran M., Camlica H., Topuz E.
American journal of clinical oncology, vol.23, no.1, pp.53-7, 2000 (SCI-Expanded)
- CXXXIII. **Crossover clinical study comparing the pharmacokinetics of etoposide (75 mg) administered as 25-mg capsules three times a day versus once a day.**
Aydiner A., Koyuncu H., Tas F., Topuz E., Disci R.
International journal of clinical pharmacology research, vol.20, pp.21-30, 2000 (SCI-Expanded)
- CXXXIV. **Long term results and prognostic factors of granulosa cell tumors of the ovary.**
SAİP P. M., Uygun K., Topuz E., BAŞARAN M., TAŞ F., AYDINER A., Aslay I., Dincer M.
ANNALS OF ONCOLOGY, vol.11, pp.87, 2000 (SCI-Expanded)
- CXXXV. **The role of chemotherapy in malignant mixed mullerian tumors of the female genital tract.**

TOPUZ E., ERALP Y., AYDINER A., Saip P. M., TAS F., YAVUZ E., Salihoglu Y.

ANNALS OF ONCOLOGY, vol.11, pp.87-88, 2000 (SCI-Expanded)

- CXXXVI. **Correlations of serum CA125 level and computerized tomography (CT) imaging with laparotomic findings following intraperitoneal chemotherapy in patients with ovarian cancer.**

TOPUZ E., AYDINER A., Saip P. M., ERALP Y., TAS F., Salihoglu Y., TENEKECI N.

European journal of gynaecological oncology, vol.21, no.6, pp.599-602, 2000 (SCI-Expanded)

- CXXXVII. **Chemotherapy in advanced breast carcinoma: Efficacy of primary and secondary or tertiary docetaxel use.**

Aydiner A., Topuz E., Argon A., Saip P., Tas F., Eralp Y., Kardas H.

ANNALS OF ONCOLOGY, vol.11, pp.37, 2000 (SCI-Expanded)

- CXXXVIII. **Nursing responsibilities in clinical trials in the Istanbul University Oncology Institute and the implementation of education programmes**

Topuz E., Aydinler A., Duma Z.

EUROPEAN JOURNAL OF CANCER, vol.35, 1999 (SCI-Expanded)

- CXXXIX. **Adjuvant intraperitoneal chemotherapy with cisplatin, mitoxantrone, 5-fluorouracil and calcium folinate in stage II-III gastric cancer**

Topuz E., Aykan F., Basaran M., Uygun K., Tas F., Sakar B., Saip P., Bugra D., Camlica H., Aydinler A.

EUROPEAN JOURNAL OF CANCER, vol.35, 1999 (SCI-Expanded)

- CXL. **Clinical pharmacokinetic comparative crossover study between three times a day and once a day-oral administration of etoposide**

AYDINER A., KOYUNCU H., TOPUZ E., Disci R.

EUROPEAN JOURNAL OF CANCER, vol.35, 1999 (SCI-Expanded)

- CXLI. **Response evaluation of bone metastases in breast cancer: Value of magnetic resonance imaging**

SAIP P. M., TENEKECI N., AYDINER A., DINCER M., INANC S., DEMIR C., Oral E. N., TOPUZ E.

CANCER INVESTIGATION, vol.17, no.8, pp.575-580, 1999 (SCI-Expanded)

- CXLII. **Factors influencing the distribution of metastases and survival in extensive disease small cell lung cancer.**

Tas F., Aydinler A., Topuz E., Camlica H., Saip P., Eralp Y.

Acta oncologica (Stockholm, Sweden), vol.38, no.8, pp.1011-5, 1999 (SCI-Expanded)

- CXLIII. **Prediction of radiological response of bone metastases to therapy by biochemical marker monitoring in patients with breast cancer: A preliminary study**

SAIP P. M., YASASEVER V., TENEKECI N., AYDINER A., INANC S., ONAT H., Disci R., TOPUZ E.

JOURNAL OF TUMOR MARKER ONCOLOGY, vol.13, no.3, pp.45-52, 1998 (SCI-Expanded)

- CXLIV. **Paraneoplastic limbic encephalitis with immature ovarian teratoma - A case report**

Aydiner A., Gurvit H., Baral I.

JOURNAL OF NEURO-ONCOLOGY, vol.37, no.1, pp.63-66, 1998 (SCI-Expanded)

- CXLV. **Intraperitoneal cisplatin-mitoxantrone and intravenous ifosfamide combination as first-line treatment of ovarian cancer**

TOPUZ E., Saip P. M., Aydinler A., Salihoglu Y., BERKMAN S., BENGISU E.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.19, no.3, pp.265-270, 1998 (SCI-Expanded)

- CXLVI. **Catheter complications associated with intraperitoneal chemotherapy**

TOPUZ E., Saip P. M., AYDINER A., Salihoglu Y., YILMAZ T., TOPUZLU C.

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.19, no.3, pp.275-279, 1998 (SCI-Expanded)

- CXLVII. **Oral etoposide in patients with small cell lung cancer**

Topuz E., Tas F., Aydinler A., Demir C., Saip P., Salepci T., Karadeniz A., Erturk N.

EUROPEAN JOURNAL OF CANCER, vol.33, pp.1072, 1997 (SCI-Expanded)

- CXLVIII. **The effects of different treatment models on Turkish women with uterine sarcoma**

BERRAK E., ASLAY I., OZTURK N., DINCER M., AYDINER A., OZBILEN S., Disci R., SAIP P. M., TOPUZ E., TORE G. G.

EUROPEAN JOURNAL OF CANCER, vol.33, pp.943, 1997 (SCI-Expanded)

- CXLIX. **Oral etoposide in patients (pts) with Kaposi's sarcoma (KS)**

Aydiner A., Tas F., Saip P., Karadeniz A., Demir C., Salepci T., Topuz E.

- EUROPEAN JOURNAL OF CANCER, vol.33, pp.1178, 1997 (SCI-Expanded)
- CL. **The effect of the interval between surgery and radiotherapy on local control and overall survival in patients with breast cancer**
 OZSEKER N., ASLAY I., DINCER M., OZBILEN S., AYDINER A., OZTURK N., CAMLICA H., Disci R., TORE G. G.
 EUROPEAN JOURNAL OF CANCER, vol.33, pp.363, 1997 (SCI-Expanded)
- CLI. **Combined effects of epirubicin and tamoxifen on the cell cycle phases in estrogen-receptor-negative Ehrlich ascites tumor cells**
 Aydiner A., Ridvanogullari M., Anil D., Topuz E., Nurten R., Disci R.
 JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.123, no.2, pp.113-117, 1997 (SCI-Expanded)
- CLII. **Intraperitoneal cisplatin - mitoxantrone in ovarian cancer patients with minimal residual disease**
 TOPUZ E., AYDINER A., SAIP P. M., BENGISU E., BERKMAN S., Disci R.
 EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.18, no.1, pp.71-75, 1997 (SCI-Expanded)
- CLIII. **Effects of cisplatin on testicular tissue and the Leydig cell-pituitary axis**
 Aydiner A., Aytekin Y., Topuz E.
 ONCOLOGY, vol.54, no.1, pp.74-78, 1997 (SCI-Expanded)
- CLIV. **ACUTE MYOCARDIAL-INFARCTION IN MAN TREATED WITH EPIRUBICIN FOR NON-HODGKIN-LYMPHOMA**
 AYDINER A., BUGRA Z., TOPUZ E., MERIC M.
 AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.18, no.5, pp.444-448, 1995 (SCI-Expanded)
- CLV. **A comparison of body image, self-esteem and social support in total mastectomy and breast-conserving therapy in Turkish women.**
 YILMAZER N., AYDINER A., OZKAN S., ASLAY I., BILGE N.
 Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, vol.2, no.4, pp.238-41, 1994 (SCI-Expanded)
- CLVI. **A comparison of body image, self-esteem and social support in total mastectomy and breast-conserving therapy in Turkish women**
 Alçalar A. N., Aydiner A., Özkan S.
 Supportive Care In Cancer, vol.2, pp.238-241, 1994 (SCI-Expanded)
- CLVII. **SERUM TUMOR-MARKERS FOR DETECTION OF BONE METASTASIS IN BREAST-CANCER PATIENTS**
 AYDINER A., TOPUZ E., DISCI R., YASASEVER v., DINCER M., DINCOL K., BILGE N.
 ACTA ONCOLOGICA, vol.33, no.2, pp.181-186, 1994 (SCI-Expanded)
- CLVIII. **POTENTIATION OF ETOPOSIDE-INDUCED DNA-DAMAGE BY VERAPAMIL IN L-STRAIN CELLS IN-VITRO**
 RIDVANOGULLARI M., AYDINER A., ANIL D., SAYIN U., DINCOL K., TOPUZ E., AYKAN F.
 JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol.12, no.4, pp.255-260, 1993 (SCI-Expanded)
- CLIX. **THE EFFICACY OF A 5-DRUG ANTIEMETIC COMBINATION DURING CHEMOTHERAPY REGIMENS CONTAINING CISPLATIN OR CYCLOPHOSPHAMIDE DOXORUBICIN**
 AYDINER A., ONAT H., OZTURK N., AYKAN F., INANC S., TOPUZ E., DINCOL K.
 JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, vol.8, no.3, pp.126-131, 1993 (SCI-Expanded)
- CLX. **TESTICULAR GERM-CELL TUMOR WITH GASTRIC METASTASIS**
 AYDINER A., OLGAC V., DARENDELILER E., OZTURK N., DINCOL K., ERSEVEN G., ONAT H.
 ACTA ONCOLOGICA, vol.32, no.4, pp.459-460, 1993 (SCI-Expanded)
- CLXI. **NEOADJUVANT CHEMOTHERAPY AND RADIOTHERAPY IN LOCALLY ADVANCED UNDIFFERENTIATED NASOPHARYNGEAL CARCINOMA**
 Onat H., Altun M., Bilge N., Karadeniz A. N., Erturk N., Aydiner A., Aykan F.
 JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol.11, pp.203-206, 1992 (SCI-Expanded)

Articles Published in Other Journals

- I. **Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study**

FERHATOĞLU F., ÇAĞATAY T., OKUMUŞ G., AYDINER A., PAKSOY N., VATANSEVER S., AYDIN E., SAİP P.

Eurasian Journal of Medical Investigation, vol.7, no.2, pp.101-106, 2023 (Peer-Reviewed Journal)

- II. **Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors**
DOĞAN İ., KHANMAMMADOV N., PAKSOY N., VATANSEVER S., SAİP P., AYDINER A.
Eurasian Journal of Pulmonology, vol.25, no.1, pp.27-32, 2023 (Peer-Reviewed Journal)
- III. **Prognostic Factors Influencing Progression-Free Survival in HER2-Positive Metastatic Breast Cancer Patients Who Were Treated with A Combination of Lapatinib and Capecitabine**
DOĞAN İ., Paksoy N., AK N., VATANSEVER S., Saip P., AYDINER A.
European Journal of Breast Health, vol.19, no.2, pp.128-133, 2023 (Scopus)
- IV. **Weekly paclitaxel treatment in the first-line therapy of classic Kaposi sarcoma: A real-life study**
Paksoy N., KHANMAMMADOV N., DOĞAN İ., Ferhatoğlu F., AHMED M. A., Karaman S., AYDINER A.
Medicine (Spain), vol.102, no.5, 2023 (Scopus)
- V. **Immunotherapy for Lung Cancer**
Karadurmuş N., AKYÜREK N., AYDINER A., SAVAŞ R., SÖNMEZ Ö., ŞENDUR M. A. N., OYAN ULUÇ B., Yalman D., Yilmaz M. U., Yilmaz Ü., et al.
Journal of Oncological Science, vol.9, no.2, pp.97-111, 2023 (Scopus)
- VI. **Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib**
DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., VATANSEVER S.
CLINICAL CANCER INVESTIGATION JOURNAL, no.4, pp.5-9, 2022 (ESCI)
- VII. **Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience**
DOĞAN İ., Khanmammadov N., Ahmed M. A., Yildiz A., Saip P., Aydiner A., VATANSEVER S.
CLINICAL CANCER INVESTIGATION JOURNAL, no.3, pp.25-29, 2022 (ESCI)
- VIII. **Effect of Astragalus Membranaceus on Patients with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study**
Ak N., Ciftci R., Cabioglu N., Aydiner A.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.36, no.2, pp.215-221, 2021 (ESCI)
- IX. **Preliminary testing of a Turkish version of the Strategies Used by Patients to Promote Health (SUPPH) Scale in a sample of breast cancer patients**
Akin S., CAN G., Durna Z., AYDINER A.
Journal of Nursing and Healthcare of Chronic Illness, vol.1, no.4, pp.303-310, 2009 (Peer-Reviewed Journal)
- X. **Immune changes in patients with locally advanced breast cancer receiving neoadjuvant chemotherapy.**
CABIOĞLU N., MÜSLÜMANOĞLU M. E., Tütüncü Y., ÇINAR S., Gürel N., Kıran B., İÇCİ A., ÖZMEN V., Dağoğlu T., AYDINER A., et al.
Türk İmmünoloji Dergisi, vol.13, pp.15-20, 2008 (Peer-Reviewed Journal)
- XI. **TREATMENT MODALITIES OF PHYLLODES TUMORS OF THE BREAST**
CABIOĞLU N., Celik T., ÖZMEN V., Igci A., Muslumanoglu M., ÖZÇINAR B., Ozluk Y., Dursun M., Dagoglu T., Aslay I., et al.
JOURNAL OF BREAST HEALTH, vol.4, no.2, pp.99-104, 2008 (ESCI)
- XII. **Predictive factors for local recurrence after breast conservative surgery following neoadjuvant chemotherapy: our long-term results**
CABIOĞLU N., Muslumanoglu M., Igci A., Ozcinar B., Ozmen V., Dagoglu T., Eralp Y., Dincer M., Aslay I., Yavuz E., et al.
TURK ONKOLOJİ DERGİSİ-TURKISH JOURNAL OF ONCOLOGY, vol.23, no.2, pp.81-90, 2008 (ESCI)
- XIII. **Clinical usefulness of serum assays of carcinoembryonic antigen and beta 2-microglobulin in the diagnosis and discrimination of metastasis of lung cancer**
Taş F., Aydiner A., Yasasever V., Dişçi R., Topuz E.
Turkish Journal of Cancer, vol.30, pp.148-154, 2000 (Scopus)
- XIV. **Lokal ileri indifferansiyenazofarenks kanserinde neoadjuvan kemoterapi ve radyoterapi**
Onat H., Altun M., Bilge N., Karadeniz A. N., Ertürk N., Aydiner A., Aykan F.

Books & Book Chapters

- I. **BREAST CANCER A GUIDE TO CLİNICAL PRACTICE**
Aydiner A. (Editor)
Springer, London/Berlin , İstanbul, 2019
- II. **BREAST DİSEASE DİAGNOSİS AND PATHOLOGY, VOLUME 1**
Aydiner A. (Editor)
Springer, London/Berlin , İstanbul, 2019
- III. **BREAST DİSEASE MAMAGEMENT AND THERAPİES, VOLUME 2**
Aydiner A. (Editor)
Springer, London/Berlin , İstanbul, 2019
- IV. **Jinekolojik Tümörler. Tanı-Tedavi-Takip**
Engin G., Aydiner A. (Editor)
Nobel Tıp Kitapevi, İstanbul, 2017
- V. **BREAST DİSEASE MANAGEMENT AND THERAPİES**
Aydiner A. (Editor)
Springer, London/Berlin , İstanbul, 2016
- VI. **BREAST DİSEASE DİAGNOSİS ANT PATHOLOGY VOLUME 1**
Aydiner A. (Editor)
Springer, London/Berlin , İstanbul, 2016
- VII. **AKCİĞER KANSERİNDE PALYATİF BAKIM**
Aydiner A. (Editor)
Nobel Tıp Kitapevi, İstanbul, 2015
- VIII. **ONKOLOJİ HEMŞİRELİĞİNDE KANITTAN UYGULAMAYA**
Aydiner A. (Editor)
Nobel Tıp Kitapevi, İstanbul, 2014
- IX. **AKCİĞERLERİ KANSERLERİNDE TEDAVİ VE BAKIM**
Aydiner A. (Editor)
Çatı Kitapları, İstanbul, 2010
- X. **Onkoloji Hemfirelininde Kan›ta Dayalı Semptom Yönetimi**
Aydiner A. (Editor)
Mavi Yayıncılık, İstanbul, 2007
- XI. **ONKOLOJİ EL KİTABI**
Aydiner A. (Editor)
Nobel Tıp Kitapevi, İstanbul, 2006
- XII. **KANSER KEMOTERAPİ DEFTERİ VE UYGULAMAYA YÖNELİK ÖNERİLER**
Aydiner A. (Editor)
Nobel Tıp Kitapevi, İstanbul, 2003
- XIII. **MEME KANSERİ**
Aydiner A. (Editor)
Nobel Tıp Kitapevi, İstanbul, 2003
- XIV. **KLİNİK ONKOLOJİ**
Aydiner A. (Editor)
İstanbul University, İstanbul, 2000
- XV. **KLİNİKTE BİYOKİMYASAL DEĞERLER VE FORMÜLLER**
Aydiner A. (Editor)
Nobel Tıp Kitapevi, İstanbul, 2000

Refereed Congress / Symposium Publications in Proceedings

- I. **Comparison of bevacizumab plus doublet chemotherapy regimens in patients with metastatic or recurrent ovarian cancer.**
Khanmammadov N., DOĞAN İ., Saip P., Aydinler A.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2023
- II. **Safety and survival in adult women with platinum sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program-LynTurk study**
Esin E., Ahmed M. A., Yildirim H. C., Mandel N. M., Erdemoglu E., SARI M., Aydinler A., Arik Z., Gumus M., BAŞARAN M., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 2 - 06 June 2023
- III. **The Contribution of 18 F-FES PET/CT in Therapy Management of Estrogen Receptor Positive Breast Cancer**
Ofas M., Has Şimşek D., Işık E. G., Cabioğlu N., İbiş K., Aydinler A., Mudun A., Şanlı Y.
35'th Annual Congress of Nuclear Medicine, Barcelona, Spain, 15 - 19 October 2022
- IV. **Outcomes and prognostic factors in patients with HER2-positive metastatic breast cancer with brain metastasis**
Dogan I., Kızıldağ Yirgin İ., Özkurt S., İbiş K., Vatansever S., Saip P. M., Aydinler A.
2022 ASCO Annual Meeting , Illinois, United States Of America, 3 - 07 June 2022, pp.14002
- V. **Timik Epitelyal Tümörlerde Ga-68 DOTATATE PET/BT Görüntüleme Caner**
Civan C., Özkan Z. G., Özkan B., Işık E. G., Has Şimşek D., Aydinler A., Kara M., Şanlı Y., Kuyumcu S., Toker A.
34. ULUSAL NÜKLEER TIP KONGRESİ , Antalya, Turkey, 27 March - 31 May 2022, pp.16
- VI. **The Contribution of 18F-FES PET/CT to Therapy Management in Estrogen Receptor Positive Breast Cancer**
Ofas M., Has Şimşek D., Işık E. G., Cabioğlu N., İbiş K., Aydinler A., Mudun A., Şanlı Y.
34. Ulusal Nükleer Tıp Kongresi, Antalya, Turkey, 27 - 31 March 2022, pp.51
- VII. **EGFR mutasyonlu Metastatik Küçük Hücreli Dışı Akciğer Kanseri Hastalarda Erlotinibin Etkinliğinin Değerlendirilmesi.**
Doğan İ., Paksoy N., Kızıldağ Yirgin İ., Aydinler A.
Ulusal Akciğer Sağlığı Kongresi 2021, Antalya, Turkey, 7 - 10 October 2021, pp.187
- VIII. **Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience**
DOĞAN İ., AYDIN E. M., AK N., İBİŞ K., Sukruoglu Ö., Erciyas S., YAZICI H., AYDINER A., SAİP P. M.
ESMO Asia Virtual Congress, ELECTR NETWORK, 20 - 22 November 2020, vol.31
- IX. **.Neoadjuvan Kemoterapi Yanıtının Değerlendirilmesinde Kısaltılmış ve Standart Diagnostik Meme MR Protokollerinin Diagnostik Değerlerinin Karşılaştırılması.**
KIZILDAĞ YIRGIN İ., YILDIZ Ş., ENGİN G., CABİOĞLU N., KARANLIK H., TÜKENMEZ M., EMİRİKÇİ S., ÖNDER S., CÜREOĞLU AYDIN E., YAVUZ E., et al.
. 15. Ulusal Meme Hastalıkları Kongresi, Antalya, Turkey, 17 - 20 October 2019
- X. **Neoadjuvan kemoterapi öncesi biyopsi ile doğrulanmış aksiller metastazı olan hasta grubunda tedavi sonrası aksiller diseksiyon göz ardı edilebilir?**
Karanlık H., Özgür İ., Bademler S., Şen F., Eralp Y., Fayda M., Küçük S., Aydinler A.
20. Ulusal Cerrahi Kongresi, 2016, Antalya, Turkey, 13 - 17 April 2016, pp.1
- XI. **İleri yaş erken evre meme kanserlerinde lokal anestezi altında meme cerrahisi.**
Karanlık H., Özgür İ., Kılıç B., Bademler S., Şen F., Eralp Y., Fayda M., Küçük S., Aydinler A.
13. Ulusal Meme Hastalıkları Kongresi, 2015, Antalya, Turkey, 21 - 25 October 2015, pp.1
- XII. **Factors affecting progression free survival in non-HIV related classical Kaposi sarcoma.**
Sen F., Tambas M., Ciftci R., Toz B., Kilic L., Bozbey H. U., Karanlik H., Kurul S., Vatansever S., Saip P., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June

2015, vol.33

- XIII. **Effect of renin-angiotensin system blockers on survival of metastatic non-small cell lung cancer patients receiving erlotinib.**
Aydiner A., Ciftci R., Sen F.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XIV. **Clinical distinguishing characteristics and management of phyllodes tumors of the breast.**
Tukenmez M., Kulle C. B., Velidedeoglu M., Agcaoglu O., Parlakgul G., Aydogan F., Onder S., Bozdogan A., Ozkurt E., Muslumanoglu M., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XV. **Investigation of mir-15a/mir-16-1 expression levels in B-cell non-Hodgkin lymphomas.**
Yazici H., kılıç S., avşar M., Sukruoglu O., AKDENİZ D., Ekenel M., Kilic L., Aydinler A., Tuncer B.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XVI. **Clinical significance of serum epithelial cell adhesion molecule (EPCAM) and vascular cell adhesion molecule-1 (VCAM-1) levels in lung cancer.**
KARABULUT S., Tastekin D., CİFTÇİ R., Tambas M., DAGOĞLU N., Guveil M. E., Tas F., Duranyildiz D., Aydinler A.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XVII. **Association of NBS1 expression with improved pathologic complete response rate in HER2-overexpressing breast cancer.**
Sen F., Yavuz E., Yegen G., Karanlık H., Tuzlali S., Aydinler A.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XVIII. **Clinicopathological characteristics and survival rate in patients with BRCA1/2 linked ovarian cancer in Turkey**
KESKİN S., EKENEL M., KILIC S., SUKRUOĞLU O., AYDINER A., ERALP Y., TOPUZ E., DALAY N., SAİP P., YAZICI H.
2nd Mediterranean Multidisciplinary Oncology Forum, İstanbul, Turkey, 17 - 19 November 2011
- XIX. **HIV-Negatif Kaposi Sarkomlu Hastalarda Serum Human Herpes Virus 8 DNA Pozitiflik Oranı**
ŞEN F., TUNÇER Ş. B., YAZICI H., KURUL S., KARANLIK H., AYDINER A.
19.Ulusal Kanser Kongresi, Antalya, Turkey, 21 - 24 April 2011, pp.311
- XX. **Kaposi Sarkomlu Hastalarda E-Cadherin Gen Mutasyonlarının Araştırılması**
TUNÇER Ş. B., ŞEN F., kılıç S., KURUL S., AYDINER A., YAZICI H., DALAY M. N.
19.Ulusal Kanser Kongresi, Antalya, Turkey, 21 - 24 April 2011, pp.502
- XXI. **HIV-Negatif Kaposi Sarkomunda Penis ve Skrotum Tutulumu**
ŞEN F., Yıldız İ., KARANLIK H., TOZ B., TUNÇER Ş. B., Ünal E., AYDINER A.
19.Ulusal Kanser Kongresi, Antalya, Turkey, 21 - 24 April 2011, pp.618
- XXII. **Meme kanseri hastalarında yeniden evrelendirme amaçlı PET-BT'nin rolü**
KUYUMCU S., KARAGÖZ F., ŞANLI Y., EKENEL M., YILDIZ İ., KARABULUT S., GEÇER F., IŞIK G., AYDINER A., SAİP P., et al.
19. Ulusal Kanser Kongresi, Antalya, Turkey, 20 - 24 April 2011, pp.423
- XXIII. **LOKAL İLERİ MEME KANSERİNDE NEOADJUVAN TEDAVİ AMAÇLI ANTRASİKLİN BAZLI KEMOTERAPİ REJİMİ İLE ANTRASİKLİNE EK OLARAK VERİLEN DOSETAKSELLİ TEDAVİ YÖNTEMLERİNİN KARŞILAŞTIRILMASI**
Canbay E., Özçınar B., Özmen V., Müslümanoğlu M. E., Eralp Y., Aydinler A., Tuzlali S., İğci A., Dağoğlu T., Kecer M., et al.
İSTANBUL MEME KANSERİ KONFERANSI VE ULUSAL MEME KANSERİ KONSENSUS TOPLANTISI 2008, İstanbul, Turkey, 21 - 25 October 2008, pp.247

- XXIV. **NEOADJUVAN KEMOTERAPİ SONRASI MEME KORUYUCU CERRAHİDE LOKAL NÜKSÜ ETKİLEYEN FAKTÖRLER: UZUN DÖNEM SONUÇLARIMIZ**
Cabioğlu N., Özçınar B., Müslümanoğlu M. E., Özmen V., İğci A., Dağoğlu T., Eralp Y., Aslay I., Yavuz E., Tunacı M., et al.
9. ULUSAL MEME HASTALIKLARI KONGRESİ, Ankara, Turkey, 5 - 09 September 2007, pp.40
- XXV. **MEMENİN FİLLODES TÜMÖRLERİNDE TEDAVİ YAKLAŞIMLARI**
Çelik T., Cabioğlu N., Özmen V., İğci A., Müslümanoğlu M. E., Özçınar B., Dağoğlu T., Kecir M., Aslay I., Aydinler A.
9. ULUSAL MEME HASTALIKLARI KONGRESİ, Ankara, Turkey, 5 - 09 September 2007, pp.47
- XXVI. **Epitelyal Over Kanserli Hastalarda Serum Leptin Düzeyinin Ca125 ve Sağkalım ile İlişkisi**
YAZAR A., TAŞ F., OĞUZ SOYDİNÇ H., CAMLICA H., ERALP Y., SAİP P., AYDINER A., TOPUZ E.
I.Tıbbi Onkoloji Kongresi, Antalya, Turkey, 29 March - 02 April 2006, pp.1
- XXVII. **İleri Evre Küçük Hücreli Dışı Akciğer Kanserinde Matriks Metalloproteinaz-9 Düzeyinin Tedavi ile Değişiminin Tedaviye Cevap Ve Sağkalım İle İlişkisi**
YAZAR A., TAŞ F., OĞUZ SOYDİNÇ H., ERTAN E., YASASEVER V., CAMLICA H., SAİP P., AYDINER A.
I.Tıbbi Onkoloji Kongresi, Antalya, Turkey, 29 March - 02 April 2006, pp.1
- XXVIII. **The efficacy of tamoxifen in patients with advanced epithelial ovarian cancer**
Karagol H., Saip P., Uygun K., Caloglu M., Eralp Y., Tas F., Aydinler A., Topuz E.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.174
- XXIX. **Induction chemotherapy followed by chemoradiotherapy in patients with stage IIIA-B non-small cell lung cancer (NSCLC)**
DAĞOĞLU SAKİN R. N., AYDINER A., Sakallioğlu B., Oztürk B., Eralp Y., SAİP P. M., ORAL E. N., KİZİR A., Topuz E.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.229
- XXX. **The combination of gemcitabine and cisplatin as neoadjuvant chemotherapy for early stage non-small cell lung carcinoma (NSCLC): An interim analysis of a phase II trial.**
Aydiner A., Kiyik M., Cikrikcioglu S., Kosar F., Gurses A., Turna A., Yazar A., Dilege S., Goksel T., Cakan A.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- XXXI. **Serum levels of leptin and proinflammatory cytokines in advanced stage non-small cell lung cancer.**
Topuz E., Tas F., Argon A., Yildiz D., Oguz H., Yasasever V., Eralp Y., Aydinler A.
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- XXXII. **Serum Levels of Leptin and Proinflammatory Cytokines in Advanced Stage Non-small Cell Lung Cancer**
TOPUZ E., TAŞ F., ARGON A., DURANYILDIZ D., OĞUZ SOYDİNÇ H., YASASEVER V., ERALP Y., AYDINER A.
2005 ASCO Annual Meeting, Orlando/Florida, United States Of America, 12 - 17 May 2005, pp.1
- XXXIII. **Induction chemotherapy with carboplatin and weekly paclitaxel followed by concomitant chemoradiation in locally advanced non-small cell lung cancer.**
Aydiner A., Topuz E., Eralp Y., Kaytan E., Oral E., Kizir A.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22
- XXXIV. **An atypical presentation of metastatic choriocarcinoma with maxillary sinus and subcutaneous involvement**
Alıcı S., Aydinler A., Eralp Y., Bulutlar G., Altun M., Budak R., Topuz E.
9th International Congress on Anti-Cancer Treatment. 2-5 Febr, 1999, Paris, France, Poster No: 16, Paris, France, 2 - 05 February 1999, pp.16
- XXXV. **Alteration in cellular immunity in patients with advanced breast cancer after neoadjuvant chemotherapy.**
Müslümanoğlu M., Cabioğlu N., Deniz G., Tütüncü Y., Çınar S., Polat N. S., İğci A., Aydinler A.
American Society of Clinical Oncology 34th Annual Meeting , California, United States Of America, 16 - 19 May 1998, pp.618

- XXXVI. **Dimethyl sulfoxide increases the antitumor cytotoxicities of 5-fluorouracil and adriamycin on FMA-3 cell line cultures in tumor colony-forming assays**
Bilir A., Ozmen V., Cabioglu N., Muslumanoglu M., Bozfakioğlu Y., Igci A., Aslay I., Erkan M., Aydinler A.
10th International Congress on Senology - Breast Diseases of the Senologic-International-Society, OPORTO, Portugal, 31 May - 04 June 1998, pp.605-611
- XXXVII. **Oral etoposide in patients with small cell lung cancer**
TOPUZ E., TAŞ F., AYDINER A., DEMİR C., SAİP P. M., SALEPÇİ T., KARADENİZ A. N., ERTÜRK N.
EUROPEAN JOURNAL OF CANCER, Oxford, United Kingdom, 01 September 1997, vol.33, no.8, pp.1072
- XXXVIII. **Oral etoposide in patients (pts) with Kaposi's sarcoma (KS)**
AYDINER A., TAS F., SAİP P. M., KARADENİZ A. N., DEMİR C., SALEPÇİ T., TOPUZ E.
EUROPEAN JOURNAL OF CANCER, Oxford, United Kingdom, 01 September 1997, vol.33, no.8, pp.1178
- XXXIX. **Dimetil sülfoksit ve antineoplastik kombinasyonların FMA3 hücre kültürlerinde koloni oluşumu üzerine etkileri**
BİLİR A., Özmen V., Müslümanoğlu M., İĞCİ A., bozfakioğlu Y., ASLAY I., ERKAN M., AYDINER A.
IV. Ulusal Meme Hastalıkları Kongresi, İzmir, Turkey, 1 - 04 March 1997, pp.95
- XL. **Adenokistik karsinomda sisplatin, epirubisin, fluorourasil (PEF) kombinasyon kemoterapinin etkinliği**
İNANÇ S., ONAT H., ALTUN M., AYDINER A., TOPUZ E.
XI. Ulusal Kanser Kongresi, Antalya, Turkey, 28 May - 02 June 1995, pp.43
- XLI. **Cisplatin, Fluorouracil and alpha-interferon for recurrent or metastatic head and neck cancer**
Inanç S., Onat H., Aydinler A., Altun M., Oral E. N., Bilge N., Topuz E.
UICC, XVI International Cancer Congress. Oct 30 -Nov 5, 1994 New Delhi, India, New Delhi, India, 30 October - 05 November 1994, pp.1
- XLII. **Lokal tedavi sonrası rezidiv, lokal nüks ve uzak metastazı olan baş-boyun kanserli hastalarda tek ajanlı kemoterapi sonuçları**
İNANÇ S., ONAT H., AYDINER A., ÖZTÜRK N., AYKAN F., ALTUN M., KARADENİZ A., DİNÇOL K.
IV. Kemoterapi Kongresi, Bursa, Turkey, 29 - 31 October 1992, pp.31
- XLIII. **Hodgkin hastalığında Sweet sendromu: bir vak'a takdimi ve literatür özeti**
ALTUN M., İNANÇ S., ONAT H., BİLGE N., AYDINER A., DARENDELİLER E., OLGAC V., KIZIR A.
XIII. Ulusal Radyoloji Kongresi, İzmir, Turkey, 21 - 23 September 1992
- XLIV. **Kemik ve sürrenal metastazlı bir hepatosellüler karsinom olgusu**
KIZIR A., AYKAN F., AYDINER A., ALTUN M., NECATİOĞLU B., ÖZTÜRK N.
XIII. Ulusal Radyoloji Kongresi, İzmir, Turkey, 21 - 23 September 1992
- XLV. **İntraperitoneal kemoterapi ile tam remisyon sağlanan bir hepatosellüler karsinom olgusu**
AYDINER A., KIZIR A., ALTUN M., ÖZTÜRK N., TOPUZ E., KARDAŞ H., EMRE A. S.
XIII. Ulusal Radyoloji Kongresi, İzmir, Turkey, 21 - 23 September 1992
- XLVI. **Lokal ileri indifferansiye nazofarenks kanserinde neoadjuvan kemoterapi ve radyoterapi**
ONAT H., ALTUN M., BİLGE N., KARADENİZ A., ERTÜRK N., ÖZTÜRK N., AYDINER A., AYKAN F.
IX. Ulusal Kanser Kongresi ve VI. Pediatrik Tümörler Kongresi, İzmir, Turkey, 2 - 07 June 1991, pp.97
- XLVII. **LOKAL İLERİ MEME KANSERİNDE HASTALIKSIZ VE GENEL SAĞKALIMI ETKİLEYEN FAKTÖRLER: UZUN DÖNEM SONUÇLARIMIZ**
Özçınar B., Cabioglu N., Özmen V., Müslümanoğlu M. E., İgci A., Kecer M., Dağoglu T., Dinçer M., Eralp Y., Tuzlali S., et al.
9. ULUSAL MEME HASTALIKLARI KONGRESİ, Ankara, Turkey, 05 September 2000 - 09 September 2007, pp.68

Supported Projects

DENİZ G., EMİROĞLU S., ÖNDER S., ABDİ A., AYDINER A., SAİP P. M., UĞUR İŞERİ S. A., TÜKENMEZ M., BAYRAM A., KÖKOĞLU A., et al., Project Supported by Higher Education Institutions, Üçlü Negatif Meme Kanserinde IFN-gama ilişkili Yolakların Rolü, 2022 - Continues

BİNGÜL İ., AYDIN A. F., AYDINER A., KÜÇÜKGERGİN C., ORAL G., Project Supported by Higher Education Institutions, Eitelyal over kanserinde serum miRNA193b ekspresyonu ve stathmin 1 düzeylerinin incelenmesi, 2022 - Continues
AYDINER A., KÜÇÜKGERGİN C., AYDIN A. F., AK N., Project Supported by Higher Education Institutions, Over kanserinde serum miRNA 214, 223 ve 181 düzeylerinin değerdendirilmesi: Tek merkezli pilot çalışma için MiRNA mikrodizi veri analizi, 2020 - Continues

Metrics

Publication: 237

Citation (WoS): 1655

Citation (Scopus): 1815

H-Index (WoS): 20

H-Index (Scopus): 22

Non Academic Experience

University, İSTANBUL ÜNİVERSİTESİ ONKOLOJİ ENSTİTÜSÜ , TIBBİ ONKOLOJİ

Professional Organization, AKCİĞER KANSERLERİ DERNEĞİ , BAŞKAN